# Satellite Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/satellite-biosciences

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.satellite.bio
- Total disclosed funding: $102M
- Latest round: Series A (Feb 25, 2022)
- Investors on record: 7

## About

Satellite Biosciences, Inc. is a biotechnology company that specializes in delivering living cells to address critical organ dysfunction, leveraging innovative technologies for therapeutic solutions.Founded in 2019 and headquartered in Cambridge, US, Satellite Biosciences, Inc. develops advanced cellular therapies. The firm was co-founded by Arnav Chhabra, Christopher Chen, and Sangeeta Bhatia, with Dave Lennon as the CEO. The company has successfully completed 2 funding rounds, with the latest being a Series A round in February 2022, raising USD 82.5 mn from prominent investors including aMoon, Polaris Partners, and Lightspeed Venture Partners, resulting in a total raised amount of USD 82.5 mn and a current valuation of USD 188.40 mn.Satellite Biosciences focuses on innovative delivery of living cells through its Tissue Therapeutics offerings, primarily the Satellite™ Adaptive Tissue (SAT) Platform. This platform enhances the engraftment and functionality of expanded, mature hepatocyte cells, utilizing technological advancements in expansion, seed formation, and stabilization to address severe diseases. Their products target patients with liver conditions requiring organ function repair or replacement and are marketed globally, including in Europe and Asia.Satellite Biosciences generates revenue through strategic partnerships with healthcare institutions, engaging in B2B transactions to provide advanced cellular therapies. Their revenue model includes licensing fees and milestone payments associated with the development of their SAT Platform, ensuring ongoing research and sustainable delivery of their tailored therapeutic solutions.Following the Series A funding round on February 25, 2022, where USD 82.5 mn was raised, Satellite Biosciences plans to utilize this capital to develop and launch new products under their Tissue Therapeutics line. The company is also targeting expansion into new geographic markets in Europe and Asia by 2024, to enhance the availability of their cellular therapies. These initiatives aim to strengthen their position in the regenerative medicine landscape and broaden access to their innovative solutions.

## Funding rounds

- Series A, Feb 25, 2022, $83M — Lightspeed Venture Partners, Polaris Partners, Waterman Capital, Alumni Ventures Group, Section 32, aMoon, Catalio Capital Management
- Seed, Nov 2, 2020, $19M — Lightspeed Venture Partners, Polaris Partners, aMoon

## Investors

- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Seed, Series A
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Seed, Series A
- aMoon (https://capitalatlas.ai/funds/amoon) — Seed, Series A
- Waterman Capital (https://capitalatlas.ai/funds/waterman-capital) — Series A
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series A
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series A
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series A